Association for Accessible Medicines

08/26/2026

PBMs were established to manage the high costs of prescription medicines, but their current opaque practices often serve to increase them – at the pharmacy counter and at the expense of taxpayers and patients.

Bottom Line: PBMs Prioritize Profits Over Affordability

Learn more: https://accessiblemeds.org/advocacy/pbm-reform/

08/04/2026

A Call for PBM Reform is A Call for Lower Drug Prices for Americans

Prescription medicine pricing and reimbursement processes must be governed by transparency, accountability, and healthy competition. To realize the full savings potential of generic and biosimilar medicines and safeguard health budgets, policymakers should take decisive steps to reform PBM practices NOW!

Learn more: https://accessiblemeds.org/advocacy/pbm-reform/

07/27/2026

Generic medicines give America's patients the confidence to thrive! In 2024, comprised 90% of all prescriptions filled, but only 12% of prescription spending. In sharp contrast, brand drugs supported patients less often— making up only 10% of prescriptions filled but adding up to 88% of the total drug spend. Learn more about what makes generic medicines unique in AAM’s : https://accessiblemeds.org/resources/blog/2025-savings-report

07/23/2026

In 2024, & saved America’s patients and the U.S. healthcare system $467 billion—and $3.4 trillion in the past 10 years. Learn more, including what can be done to help safeguard this important industry: https://accessiblemeds.org/resources/blog/2025-savings-report

07/17/2026

In the past decade, and medicines have saved the U.S. healthcare system $3.4 trillion. Still, threats to the sustainability of this essential industry remain. Policymakers must ACT NOW to streamline FDA processes, curb patent abuse, stop PBMs and Medicare policies from denying patient access, and rollback harmful federal policies – including IRA price controls – to safeguard the livelihood of America’s patients. Learn more in the : https://accessiblemeds.org/resources/blog/2025-savings-report

07/14/2026

The average market entry of a first generic is between 12 and 14 years; and approximately 18 years for a first biosimilar. One thing is clear: The Inflation Reduction Act (IRA) harms generic and biosimilar medicine competition and it must be amended– especially to promote more robust biosimilar competition. https://accessiblemeds.org/resources/blog/2025-savings-report

07/08/2026

Access! 2027 is set for March 1-3, and registration is now open!
Join the leaders moving the generic and biosimilar medicines industry forward. Don't miss this opportunity: https://access.accessiblemeds.org/
Biosimilars Council

07/08/2026

06/30/2026

and provide critical savings throughout the U.S. healthcare system and are particularly valuable to Medicare and the patients they serve. In 2024, the use of generics saved $142 billion in Medicare and $62 billion in Medicaid. Learn more about savings from this essential industry and what can be done to ensure America’s patients can thrive with access to these lower-cost medications: : https://accessiblemeds.org/resources/blog/2025-savings-report